https://techpapersworld.com/wp-content/uploads/2022/06/Press-Release-Nexviadyme®-avalglucosidase-alfa-1280x720.jpg

The European Commission has granted marketing authorization for Nexviadyme® (avalglucosidase alfa), an enzyme replacement therapy (ERT) for the long-term treatment of both late-onset and infantile-onset Pompe disease, a rare, progressive and debilitating muscle disorder. Nexviadyme is the first and only newly approved medicine for Pompe disease in Europe since 2006, when the European Commission authorized the marketing of alglucosidase alfa, branded Myozyme®. Benedikt Schoser, MD. Senior Consultant and Professor, Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians-University Munich “The approval...

https://techpapersworld.com/wp-content/uploads/2022/06/Bureau-Veritas-acquires-Advanced-Testing-Laboratory-1280x720.jpg

Bureau Veritas acquires Advanced Testing Laboratory, a US leader in scientific sourcing Expanding BV’s footprint in Consumer Products and Consumer Healthcare markets Bureau Veritas, a world leader in testing, inspection and certification, announced the acquisition of Advanced Testing Laboratory (ATL), a leader in scientific sourcing services for the North American Consumer Healthcare Products, Cosmetics & Personal Care and Medical Device markets. Headquartered in Cincinnati, Ohio, ATL’s services span the entire product life cycle, from research and development to substance and product qualification to manufacturing....

https://techpapersworld.com/wp-content/uploads/2022/06/Bombardier-Announces-Expiration-of-Early-Tender-1280x720.jpg

Bombardier Inc. (“Bombardier” or the “Corporation”) today announced certain matters with respect to its cash tender offer previously announced on June 13, 2022 (the “Tender Offer”) to purchase for cash up to US$350,000,000 aggregate purchase price (exclusive of Accrued Interest) (as such aggregate purchase price may be increased or decreased by the Corporation, the “Aggregate Maximum Purchase Amount”) of three series of its outstanding senior notes (collectively, the “Notes”) due 2027, 2024 and 2025 as identified...

https://techpapersworld.com/wp-content/uploads/2022/06/Flex-LNG-Announce-24-years-of-new-contract-1280x720.jpg

Hamilton, Bermuda. Flex LNG agrees 24 years of backlog for three LNG carriers Flex LNG, Ltd. (“Flex LNG” or the “Company”) (OSE/NYSE: FLNG) is pleased to announce new Time Charter Agreements for Flex Rainbow, Flex Enterprise and Flex Amber which are the three open positions we have been marketing. Flex LNG and the Charterer of Flex Enterprise and Flex Amber, a supermajor, have agreed to replace the existing variable Time Charters which are due October 2023 and March 2024...

https://techpapersworld.com/wp-content/uploads/2022/06/Umicore-launches-Umicore-2030-1280x720.jpg

Umicore will hold today its Capital Markets Day for investors and analysts at 09:00 BST/10:00 CEST. The event is being held in London and will also be streamed via live webcast, which can be found at: Umicore Capital Markets Day Chief Executive Officer Mathias Miedreich, along with his Management Board colleagues, will unveil Umicore’s new strategy “Umicore 2030 – RISE”. The strategy is underpinned by following key elements: Continuity in Umicore’s strategic journey by further building...

https://techpapersworld.com/wp-content/uploads/2022/06/Press-release-Biocartis-Group-NV-1-1280x720.jpg

Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces the CE-marking of its fully automated Idylla™ GeneFusion Panel (CE-IVD). The Panel detects in one single cartridge ALK, ROS1, RET and METex14 skipping, a wide range of actionable targets relevant in non-small cell lung cancer (NSCLC). Designed for use in clinical laboratories, the Panel provides comprehensive testing results within 180 minutes, significantly faster than currently available testing methods which often take days...

https://techpapersworld.com/wp-content/uploads/2022/06/Press-release-Biocartis-Group-NV-1280x720.jpg

Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces a double milestone today: the selling of its one-millionth commercial Idylla™ cartridge and the placement of its 2,000th Idylla™ instrument since its commercial launch. These events mark a key commercial milestone for Biocartis, which has been commercializing its rapid and easy-to-use decentralized Idylla™ molecular diagnostics platform in more than 70 countries across the world since 2015. Biocartis launched its first commercial...

https://techpapersworld.com/wp-content/uploads/2022/06/U.S.-News-Reveals-the-2022-1280x720.jpg

U.S. News & World Report, the global authority in hospital rankings and consumer advice, today revealed the 2022-2023 Best Children’s Hospitals rankings to help families of children with rare or life-threatening illnesses find the best medical care available. Now in their 16th year, the rankings include new measures for diversity, equity and inclusion. The 2022-2023 rankings highlight the top 50 centers in each of these 10 pediatric specialties: cancer, cardiology & heart surgery, diabetes & endocrinology, gastroenterology & gastrointestinal surgery,...

https://techpapersworld.com/wp-content/uploads/2022/06/International-Petroleum-Corporation-Announces-1280x720.jpg

NOT FOR DISTRIBUTION IN OR TO, OR TO ANY PERSON LOCATED IN OR RESIDING IN ANY JURISDICTION WHERE THE ISSUANCE, PUBLICATION OR DISTRIBUTION OF THIS DOCUMENT IS PROHIBITED BY LAW. DISTRIBUTION OF THIS DOCUMENT MAY BE CONTRARY TO THE LAW IN CERTAIN JURISDICTIONS. International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) is pleased to announce that it has amended the terms of its previously announced substantial issuer bid (the Offer) to purchase for cancellation up...

https://techpapersworld.com/wp-content/uploads/2022/06/MCH-Group-Ad-hoc-announcement-1280x720.jpg

MCH Group appoints new CEO MCH Group Ltd., based in Basel/Switzerland, is pleased to announce the appointment of its new Group CEO. As of July 1, 2022, Florian Faber, MBA, will be Group Chief Executive Officer. He will take over from Beat Zwahlen, who has been leading the Group through very difficult times in the last 18 months. Florian Faber is the Head of the Live Marketing Solutions (LMS) Division and has been with MCH...